Skip to main content
. 2016 Nov 18;1(5):e000094. doi: 10.1136/esmoopen-2016-000094

Figure 1.

Figure 1

DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. Following patient consent and study enrolment, biopsies are taken and processed in a certified laboratory using standardised protocols and storage methods. Pathological diagnosis and tumour cell content are validated by an independent pathologist. After DNA and RNA isolation and library preparation, NGS on an Illumina HiSeq 2500 platform is performed. Bioinformatical analysis is followed by data curation and validation of putative molecular targets. Following discussion in a molecular tumour board meeting, further enrolment in clinical trials and other personalised treatment strategies are recommended. CNV, copy number variant; FISH, fluorescence in situ hybridisation; NGS, next-generation sequencing; NCT IIT, National Center for Tumour Diseases investigator initiated trial; qRT-PCR, quantitative real-time polymerase chain reaction; SNV, single nucleotide variant.